Previous 10 | Next 10 |
SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of up to $503 million and tiered royalties. GSK obtains the exclusive rights to ibrexafungerp; SCYNEXIS retains rights to all other assets in its proprietary class of enfumafungin-derived ...
2023-05-11 07:47:50 ET SCYNEXIS press release ( NASDAQ: SCYX ): Q1 GAAP EPS of -$0.71. Revenue of $1.13M (+63.8% Y/Y). For further details see: SCYNEXIS GAAP EPS of -$0.71, revenue of $1.13M
SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME ® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment from GSK of $90 million upon deal close with future performance-based milestone...
2023-04-24 09:13:55 ET Cidara Therapeutics ( NASDAQ: CDTX ) announced Monday that it received a $20M milestone payment from its partner Melinta Therapeutics ( OTCPK:MLNTQ ) following the FDA approval of candidemia treatment Rezzayo last month. The U.S. approved the once we...
JERSEY CITY, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of interim data across a diverse array of infecti...
2023-04-05 08:31:04 ET Secoo Holding ( SECO ) -22% . The NFT Gaming Company ( NFTG ) -16% . Assure Holdings ( IONM ) -12% . Bullfrog AI Holdings ( BFRG ) -11% . Alarum Technologies ( ALAR ) -10% . Guardforce AI ( GFAI ) -8%...
2023-03-31 11:47:43 ET Summary GSK and SCYNEXIS signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal candidiasis. GSK will pay SCYNEXIS $90 million upfront, with additional milestone payments and royalties. SCYNEXIS retains rights to ot...
2023-03-31 08:39:40 ET SCYNEXIS press release ( NASDAQ: SCYX ): Q4 GAAP EPS of -$0.30 beats by $0.10 . Revenue of $1.4M (+133.3% Y/Y) beats by $0.13M . SCYNEXIS ended Q4 2022 with cash, cash equivalents and short-term investments of $73.5 million, and upon clos...
SCYNEXIS announced it has signed an exclusive agreement with GSK to commercialize and further develop BREXAFEMME ® (ibrexafungerp tablets) for all indications. GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties. ...
2023-03-31 06:00:00 ET 3 Ways to Use Technical Analysis to Find Winning Penny Stocks Penny stocks, often defined as shares trading below $5, have long been a magnet for investors seeking opportunities to capitalize on the potential for rapid growth and high returns. While many perceive ...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...